The glucagon-like peptide-1-based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys

Diabetes, Obesity and Metabolism

Volumn 16, Issue 10, 2014, Pages 910-921

  Roy, D ^a   Chadwick, K D ^a   Tatarkiewicz, K ^a   LaCerte, C ^a   Bergholm, A M ^b   Brodie, T ^a   Mangipudy, R S ^a   Parkes, D ^a   Graziano, M J ^a   Reilly, Timothy P ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

DPP4; Exenatide; GLP 1; Saxagliptin

Indexed keywords

EXENDIN 4; SAXAGLIPTIN; ADAMANTANE; DIPEPTIDE; GLUCAGON LIKE PEPTIDE 1; PEPTIDE; VENOM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANIMAL WELFARE; ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; EXPERIMENTAL DOG; EXPERIMENTAL MONKEY; FEMALE; FOOD AND DRUG ADMINISTRATION; GOOD LABORATORY PRACTICE; MALE; MOUSE; NONHUMAN; PANCREAS DISEASE; PANCREAS ISLET CELL HYPERPLASIA; PROTOCOL COMPLIANCE; RAT; TREATMENT DURATION; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; DIABETES MELLITUS, EXPERIMENTAL; DOG; DRUG EFFECTS; HAPLORHINI; MAXIMUM TOLERATED DOSE; ORGAN SIZE; PANCREAS; PATHOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION;

ADAMANTANE; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIPEPTIDES; DOGS; GLUCAGON-LIKE PEPTIDE 1; HAPLORHINI; INJECTIONS, SUBCUTANEOUS; MAXIMUM TOLERATED DOSE; MICE; ORGAN SIZE; PANCREAS; PEPTIDES; RATS; VENOMS;

EID: 84912522845     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12294     Document Type: Article

References (80)

1. Kolterman OG, Buse JB, Fineman MS et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 3082-3089.
2. Parkes DG, Pittner R, Jodka C, Smith P, Young A. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 2001; 50: 583-589.
3. Egan JM, Clocquet AR, Elahi D. The insulinotropic effect of acute exendin- 4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 2002; 87: 1282-1290.
4. Fehmann HC, Habener JF. Insulinotropic hormone glucagon-like peptide- I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology 1992; 130: 159-166.
5. Gedulin BR, Nikoulina SE, Smith PA et al. Exenatide (exendin-4) improves insulin sensitivity and β-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 2005; 146: 2069-2076.
6. Parkes D, Gedulin B, Smith P, Young A. Effect of exendin-4 on glucagon secretion in lean and obese Zucker (ZDF) rats (Abstract). Diabetes 2001; 50: A313.
7. Wang Q, Brubaker PL. Akt1 mediates GLP-1-stimulated beta cell proliferation and protection from apoptosis in INS-1 cells (Abstract). Diabetes 2002; 51: A344.
8. Wang Q, Brubaker PL. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 2002; 45: 1263-1273.
9. Jodka C. Exendin-4 potently regulates gastric emptying in rats (Abstract). Diabetes 1998; 47: A403.
10. Ahmad SR, Swann J. Exenatide and rare adverse events. N Engl J Med 2008; 358: 1970-1971.
11. Ayoub WA, Kumar AA, Naguib HS, Taylor HC. Exenatide-induced acute pancreatitis. Endocr Pract 2010; 16: 80-83.
12. Cure P, Pileggi A, Alejandro R. Exenatide and rare adverse events. N Engl J Med 2008; 358: 1969-1970.
13. Denker PS, Dimarco PE. Exenatide (exendin-4)-induced pancreatitis: a case report. Diabetes Care 2006; 29: 471.
14. Garber A, Henry R, Ratner R et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473-481.
15. Tripathy NR, Basha S, Jain R, Shetty S, Ramachandran A. Exenatide and acute pancreatitis. J Assoc Physicians India 2008; 56: 987-988.
16. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide-the FDA's review of a new antidiabetic therapy. N Engl J Med 2010; 362: 774-777.
17. US Food and Drug Administration. Information for healthcare professionals: exenatide (marketed as Byetta) - 8/2008 update. 2008. Available from URL: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm. Accessed 11 September 2013.
18. US Food and Drug Administration. Information for healthcare professionals - acute pancreatitis and sitagliptin (marketed as Januvia and Janumet). 2009. Available from URL: http://www.fda.gov/Drugs/Drug Safety/PostmarketDrugSafetyInformationforPatientsandProviders/Drug SafetyInformationforHeathcareProfessionals/ucm183764.htm. Accessed 11 September 2013.
19. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 2013; 173: 534-539.
20. Dore DD, Bloomgren GL, Wenten M et al. A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab 2011; 13: 559-566.
21. Dore DD, Seeger JD, Arnold CK. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009; 25: 1019-1027.
22. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013; 62: 2595-2604.
23. Kahn SE. Incretin therapy and islet pathology: a time for caution. Diabetes 2013; 62: 2178-2180.
24. Bonner-Weir S, In't Veld PA, Weir GC. Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies. Diabetes Obes Metab 2014; 16: 661-666.
25. Harja E, Lord J, Skyler JS. An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology. Diabetes Technol Ther 2013; 15: 609-618.
26. Nachnani JS, Bulchandani DG, Nookala A et al. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia 2010; 53: 153-159.
27. Tatarkiewicz K, Smith PA, Sablan EJ et al. Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents. Am J Physiol Endocrinol Metab 2010; 299: E1076-1086.
28. Gier B, Matveyenko AV, Kirakossian D, Dawson D, Dry SM, Butler PC. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model. Diabetes 2012; 61: 1250-1262.
29. Matveyenko AV, Dry S, Cox HI et al. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes 2009; 58: 1604-1615.
30. Busch SJ, Hoffmann P, Sahota P et al. Studies in rodents with the dipeptidyl peptidase-4 inhibitor vildagliptin to evaluate possible druginduced pancreatic histological changes that are predictive of pancreatitis and cancer development in man. Diabetes Obes Metab 2013; 15: 72-76.
31. Engel SS, Williams-Herman DE, Golm GT et al. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract 2010; 64: 984-990.
32. Nyborg NC, Molck AM, Madsen LW, Knudsen LB. The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species. Diabetes 2012; 61: 1243-1249.
33. Koehler JA, Baggio LL, Lamont BJ, Ali S, Drucker DJ. Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes 2009; 58: 2148-2161.
34. Tatarkiewicz K, Belanger P, Gu G, Parkes D, Roy D. No evidence of druginduced pancreatitis in rats treated with exenatide for 13 weeks. Diabetes Obes Metab 2013; 15: 417-426.
35. Vrang N, Jelsing J, Simonsen L et al. The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis. Am J Physiol Endocrinol Metab 2012; 303: E253-264.
36. Aston-Mourney K, Subramanian SL, Zraika S et al. One year of sitagliptin treatment protects against islet amyloid-associated beta-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice. Am J Physiol Endocrinol Metab 2013; 305: E475-484.
37. Code of Federal Regulations. Title 9, Animals and Animal Products. Washington DC: National Archives and Records Administration, Office of the Federal Register, 2013.
38. Code of Federal Regulations. Title 21, part 58, Good Laboratory Practice for Nonclinical Laboratory Studies.
39. Neef N, Nikula KJ, Francke-Carroll S, Boone L. Regulatory forum opinion piece: blind reading of histopathology slides in general toxicology studies. Toxicol Pathol 2012; 40: 697-699.
40. Denda A, Tsutsumi M, Konishi Y. Exocrine pancreas. In: Mohr U, Dungworth DL, Capen CC, eds. Pathobiology of the Aging Rat, Vol. 2. Washington, DC: ILSI Press, 1994; 351-360.
41. Hansen JF, Ross PE, Makovec GT, Eustis SL, Sigler RE. Proliferative and other selected lesions of the exocrine pancreas in rats. In: Guides for Toxicologic Pathology, Vol. GI-6. Washington, DC: Society of Toxicologic Pathologist, American Registry of Pathology, and Armed Forces Institute of Pathology, 1995; 2-7.
42. Mohr U. International classification of rodent tumours. In: Part 1: The Rat Fascicle No. 10: Digestive System. Lyon: International Agency for Research on Cancer, 1997; 85-91.
43. Carroll RJ, Schneider H. A note on Levene's test for equality of variance. Stat Probab Lett 1985; 3: 191-194.
44. Sokal RR, Rohlf FJ. Assumptions of analysis of variance. In: Biometry: the Principles and Practice of Statistics in Biological Research. 3rd edn. New York: W. H. Freeman and Co, 1995; 392-450.
45. Dunnett CW. A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc 1955; 50: 1096-1121.
46. Welsh BL. The generalization of Student's problem when several different population variances are involved. Biometrika 1947; 34: 28-35.
47. Kirk RE. Experimental Design: Procedures for the Behavioral Sciences. Brooks/Cole: New York, 1968.
48. Kruskal WH, Wallis WA. Use of ranks in one-criterion variance analysis. J Am Stat Assoc 1952; 47: 583-634.
49. Kruskal WH, Wallis WA. Errata to Use of ranks in one-criterion variance analysis. J Am Stat Assoc 1953; 48: 907-911.
50. Shirley E. A non-parametric equivalent of Williams' test for contrasting increasing dose levels of a treatment. Biometrics 1977; 33: 386-389.
51. Steel RGD. A multiple comparison rank sum test: treatments versus control. Biometrics 1959; 15: 560-572.
52. Tarone RE. Tests for trend in life table analysis. Biometrika 1975; 62: 679-682.
53. Lin KK, Ali MW. Statistical review and evaluation of animal tumorogenicity studies. In: Buncher CR, Tsay JY, eds. Statistics in the Pharmaceutical Industry. New York: Marcel Dekker, 1994; 19-57.
54. US Department of Health and Human Services. Guidance for Industry: Statistical Aspects of the Design, Analysis, and Interpretation of Chronic Rodent Carcinogenicity Studies of Pharmaceuticals. Draft Guidelines. Rockville: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2001.
55. Peto R, Pike MC, Day NE et al. Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal experiments. In: Longterm and Short-term Screening Assays for Carcinogens: a Critical Appraisal. IARC Monographs, Vol. 2. Lyon: IARC, 1980; 311-426.
56. Koehler JA, Drucker DJ. Activation of glucagon-like peptide-1 receptor signaling does not modify the growth or apoptosis of human pancreatic cancer cells. Diabetes 2006; 55: 1369-1379.
57. Amylin Pharmaceuticals. BYETTA® (exenatide) injection. Prescribing information. 2011. Available from URL: http://documents.byetta.com/Byetta_PI.pdf. Accessed 12 September 2013.
58. Microscopic findings historical data for Sprague-Dawley rats. 2013. Available from URL: http://www.criver.com. Accessed 27 September 2013.
59. Boorman GA, Eustis SL. Atrophy, exocrine pancreas, rat. In: Jones TC, Mohr U, Hunt RD, eds. Monographs on Pathology of Laboratory Animals: Digestive System. New York: Springer-Verlag, 1985; 239-245.
60. Klimstra DS, Hruban RH, Pitman MB. Pancreas. In: Mills SE, ed. Histology for Pathologists. 3rd edn. Philadelphia: Lippincott Williams and Wilkins, 2007; 723-760.
61. Bristol-Myers Squibb. ONGLYZA (saxagliptin) tablets. Prescribing information. 2013. Available from URL: http://packageinserts.bms.com/pi/pi_onglyza.pdf. Accessed 12 September 2013.
62. Hummer T. FDA surveillance of adverse drug effects. NIDDK Workshop on Pancreatitis, Diabetes and Pancreatic Cancer. Lister Hill Auditorium, NIH, Bethesda, MD, June 12-13, 2013.
63. ElashoffM, Matveyenko AV, Gier B, ElashoffR, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011; 141: 150-156.
64. Yu X, Tang H, Huang L, Yang Y, Tian B, Yu C. Exenatide-induced chronic damage of pancreatic tissue in rats. Pancreas 2012; 41: 1235-1240.
65. Chadwick KD, Roy D, Fletcher A et al. Occurrence of spontaneous pancreatic lesions in normal and diabetic rats may confound the nonclinical assessment of glucagon-like peptide (GLP)-1 elevating therapies. NIDDK Workshop on Pancreatitis, Diabetes and Pancreatic Cancer. Lister Hill Auditorium, NIH, Bethesda, MD, June 12-13, 2013.
66. Butler PC, Matveyenko AV, Dry S, Bhushan A, ElashoffR. Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire? Diabetologia 2010; 53: 1-6.
67. Hruban RH, Iacobuzio-Donahue C. The pancreas. In: Kumar V, Abbas AK, Fausto N, Aster JC, eds. Pathologic Basis of Disease. 8th edn. Philadelphia: Saunders Elsevier, 2010; 891-904.
68. Eustis SL, Boorman GA, Hayashi Y. Exocrine pancreas. In: Boorman GA, Eustis SL, Elwell MR, Montgomery CA, MacKenzie WF, eds. Pathology of the Fischer Rat. San Diego: Academic Press Inc, 1990; 95-108.
69. Greaves P. Exocrine and endocrine pancreas. Histopathology of Preclinical Toxicity Studies. 4th. Amsterdam: Elsevier 2013; 489-536.
70. Forest T, Holder D, Smith A et al. Characterization of the exocrine pancreas in the Zucker diabetic fatty (ZDF) rat model of Type 2 diabetes (T2DM) treated with sitagliptin, a dipepidyl peptidase-4 (DPP-4) inhibitor. NIDDK Workshop on Pancreatitis, Diabetes and Pancreatic Cancer. Lister Hill Auditorium, NIH, Bethesda, MD, June 12-13, 2013.
71. Vahle J, Byrd R, Blackbourne J et al. Evaluation of serum amylase and lipase, and expanded pancreatic histology in monkeys following 12-month administration of dulaglutide. NIDDK Workshop on Pancreatitis, Diabetes and Pancreatic Cancer. Lister Hill Auditorium, NIH, Bethesda, MD, June 12-13, 2013.
72. Fiorentino TV, Owston M, Abrahamian G et al. Chronic continuous exenatide infusion does not cause pancreatitis or ductal hyperplasia in baboons. A 14 weeks longitudinal controlled study. Diabetes 2013; 62: A263.
73. Butler PC, Dry S, ElashoffR. GLP-1-based therapy for diabetes: what you do not know can hurt you. Diabetes Care 2010; 33: 453-455.
74. Wallig MA, Sullivan JM. Exocrine pancreas. In: Haschek WM, Rousseaux CG, Wallig MA, eds. Toxicologic Pathology. 3rd edn. Amsterdam: Elsevier, 2013; 2362-2390.
75. Chiu WY, Shih SR, Tseng CH. A review on the association between glucagonlike peptide-1 receptor agonists and thyroid cancer. Exp Diabetes Res 2012; 2012: 924168.
76. Nauck MA, Friedrich N. Do GLP-1-based therapies increase cancer risk? Diabetes Care 2013; 36: S245-252.
77. Liang J, Leung KK, Lam SY, Leung PS. Combined treatment with a dipeptidyl peptidase-IV inhibitor (sitagliptin) and an angiotensin II type 1 receptor blocker (losartan) promotes islet regeneration via enhanced differentiation of pancreatic progenitor cells. Diabetes Obes Metab 2012; 14: 842-851.
78. Mu J, Petrov A, Eiermann GJ et al. Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. Eur J Pharmacol 2009; 623: 148-154.
79. Drucker DJ. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes 2013; 62: 3316-3323.
80. Panjwani N, Mulvihill EE, Longuet C et al. GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. Endocrinology 2013; 154: 127-139.